Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro.
Morphogenesis of the demyelinating lesions in Baló's concentric sclerosis.
Cervical cord and ventricle affection in neuromyelitis optica.
Tract-specific and age-related variations of the spinal cord microstructure: a multi-parametric MRI study using diffusion tensor imaging (DTI) and inhomogeneous magnetization transfer (ihMT).
Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin.
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.
Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies.
Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis.
Gastro Effects Dog Oral MS Drug Tecfidera
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis.
Standing up in multiple sclerosis (SUMS): protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis.
Neurovascular coupling in patients with relapsing-remitting multiple sclerosis.
Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus.
Differential transcriptional response profiles in human myeloid cell populations.
Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact.
Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells.
Trimesta (Oral Estriol)
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis Patients
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression.
Sphingosine-1-Phosphate (S1P) Impacts Presynaptic Functions by Regulating Synapsin I Localization in the Presynaptic Compartment.
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis.
Burden of neurological conditions in Canada.
Neurotrophic and Neuroprotective effects of muscle contraction.
Teriflunomide
Pages
« first
‹ previous
…
75
76
77
78
79
80
81
82
83
…
next ›
last »